-
EP2143432
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2143432
| EP2143432 - 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 07.12.2012 Database last updated on 06.11.2024 | Most recent event Tooltip | 07.12.2012 | Application deemed to be withdrawn | published on 09.01.2013 [2013/02] | Applicant(s) | For all designated states Bayer Pharma Aktiengesellschaft Müllerstrasse 178 13353 Berlin / DE | [2011/34] |
| Former [2010/02] | For all designated states Bayer Schering Pharma Aktiengesellschaft Müllerstrasse 178 13353 Berlin / DE | Inventor(s) | 01 /
Fritzemeier, Karl-Heinrich GTR TRG Women's Healthcare Bayer Schering Pharma AG Rabenstr. 5a 13505, Berlin / DE | 02 /
Diel, Patrick Molekulare und zelluläre Sportmedizin Institut für 50933, Köln / DE | 03 /
Hertrampf, Torsten Institut für Kreislaufforschung und Sportmedizin Molekulare und zelluläre Sportmedizin Carl-Diem-Weg 6 50933, Köln / DE | [2010/02] | Application number, filing date | 08160239.3 | 11.07.2008 | [2010/02] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2143432 | Date: | 13.01.2010 | Language: | EN | [2010/02] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 09.10.2008 | Classification | IPC: | A61K31/565, A61K31/567, A61P35/00 | [2010/02] | CPC: |
A61K31/565 (EP,KR,US);
A61K31/567 (EP,KR,US);
A61K31/56 (KR);
A61P1/00 (EP);
A61P35/00 (EP)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2010/02] | Title | German: | 9-Alpha-Estratrien-Derivate als ER-Beta-selektive Liganden zur Prävention und Behandlung von Darmkrebs | [2010/02] | English: | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer | [2010/02] | French: | Dérivés d'estratriènes 9-alpha en tant que ligands sélectifs ER-beta pour la prévention et le traitement du cancer intestinal | [2010/02] | Examination procedure | 13.07.2010 | Examination requested [2010/33] | 05.08.2010 | Despatch of a communication from the examining division (Time limit: M04) | 09.12.2010 | Reply to a communication from the examining division | 06.03.2012 | Communication of intention to grant the patent | 16.07.2012 | Fee for grant paid | 16.07.2012 | Fee for publishing/printing paid | 17.07.2012 | Application deemed to be withdrawn, date of legal effect [2013/02] | 23.08.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2013/02] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 05.08.2010 | Fees paid | Renewal fee | 27.07.2010 | Renewal fee patent year 03 | 01.08.2011 | Renewal fee patent year 04 | 31.07.2012 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [DA]WO0177139 (SCHERING AG [DE], et al) [DA] 1-9* claims 26,27 *; | [DX]WO03104253 (SCHERING AG [DE]) [DX] 2,3,6-9 * claim 5 *; | [X]WO2005051401 (SCHERING AG [DE], et al) [X] 2,3,6-9 * claims *; | [DX]WO2007062877 (SCHERING AG [DE], et al) [DX] 2,4,6-9 * claim 8 * | by applicant | WO9602277 | WO0177139 | WO03104253 | WO2007062877 | - J. STEROID BIOCHEM. MOLEC. BIOL, (1995), vol. 55, pages 395 - 403 | - EXP. OPINION INVEST. DRUGS, (1998), vol. 7, pages 575 - 589 | - "Ullmans Encykiopadie der technischen Chemie", ULLMAN'S ENCYCLOPEDIA OF INDUSTRIAL CHEMISTRY, (1953), vol. 4, pages 1 - 39 | - JOURNAL OF PHARMACEUTICAL SCIENCES, (1963), vol. 52, page 918 FF | - "Adjuvants for Pharmaceutics and Related Fields", PHARM. IND., (1961), vol. 2, page 72 | - BOOTH C ET AL., "In vivo administration of genistein has no effect on small intestinal epithelial proliferation and apoptosis, but a modest effect on clonogen survival", CANCER LETT, (1999), vol. 144, no. 2, doi:doi:10.1016/S0304-3835(99)00220-7, pages 169 - 75, XP055213198 DOI: http://dx.doi.org/10.1016/S0304-3835(99)00220-7 | - NELSON HD ET AL., "Postmenopausal hormone replacement therapy: scientific review", JAMA, (2002), vol. 288, no. 7, pages 872 - 81 | - ROSSOUW,J.; ANDERSON,G.; PRENTICE,R. ET AL., "Risks and benefits of estrogen and progesterone in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial", J. AM. MED. ASSOC., (2002), vol. 288, pages 321 - 333 | - WADA-HIRAIKE O ET AL., "Role of estrogen receptor beta in colonic epithelium", PROC NATL ACAD SC USA, (2006), vol. 103, no. 8, pages 2959 - 64 | - CHLEBOWSKI RT ET AL., "Estrogen plus progestin and colorectal cancer in postmenopausal women", N ENGL J MED, (2004), vol. 350, no. 10, pages 991 - 1004 | - FARQUHAR CM ET AL., "Long term hormone therapy for perimenopausal and postmenopausal women", COCHRANE DATABASE SYST REV, (2005), no. 3, page 004143 | - DINGER JC ET AL., "Colon cancer risk and different HRT formulations: a case-control study", BMC CANCER, (2007), vol. 7, doi:doi:10.1186/1471-2407-7-76, page 76, XP021023158 DOI: http://dx.doi.org/10.1186/1471-2407-7-76 | - CARPENTER KD; KORACH KS, "Potential biological functions emerging from the different estrogen receptors", ANN N Y ACAD SCI, (2006), vol. 1092, pages 361 - 73 | - CAMPBELL-THOMPSON M; LYNCH IJ; BHARDWAJ B, "Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer", CANCER RES 15, (2001), vol. 61, no. 2, pages 632 - 40 | - KONSTANTINOPOULOS PA ET AL., "Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation", EUR J CANCER, (2003), vol. 39, no. 9, doi:doi:10.1016/S0959-8049(03)00239-9, pages 1251 - 8, XP004425216 DOI: http://dx.doi.org/10.1016/S0959-8049(03)00239-9 | - XIE LQ; YU JP; LUO HS, "Expression of estrogen receptor beta in human colorectal cancer", WORLD J GASTROENTEROL, (2004), vol. 10, no. 2, pages 214 - 7 | - MARTINETI V ET AL., "ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components", ENDOCR RELAT CANCER, (2005), vol. 12, no. 2, pages 455 - 69 | - JASSAM N ET AL., "Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging", ONCOL REP, (2005), vol. 14, no. 1, pages 17 - 21 | - WADA-HIRAIKE O; WARNER M; GUSTAFSSON JA, "New developments in oestrogen signalling in colonic epithelium", BIOCHEM SOC TRANS, (2006), vol. 34, no. 6, pages 1114 - 6 | - LECHNER D; KALLAY E; CROSS HS, "Phytoestrogens and colorectal cancer prevention", VITAM HORM, (2005), vol. 70, pages 169 - 98 | - BERTAGNOLI M ET AL., CANCER RES., (20010315), vol. 61, no. 6, pages 2547 - 51 | - BERTAGNOLI M ET AL., CARCINOGENESIS, (2005), vol. 26, no. 3, pages 587 - 95 | - KOORNSTRA JJ ET AL., "Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas", HISTOPATHOLOGY, (2004), vol. 44, no. 1, pages 9 - 17 | - HERTRAMPFT ET AL., "Analysis of the effects of oestrogen receptor alpha (ERalpha)- and ERbeta- selective ligands given in combination to ovariectomized rats", BR J PHARMACOL., (2008), vol. 153, no. 7, pages 1432 - 7 | - DIEL P ET AL., "The differential ability of the phytoestrogen genistein and of estradiol to induce uterine weight and proliferation in the rat is associated with a substance specific modulation of uterine gene expression", MOL AND CELL ENDOCRINOL 30, (2004), vol. 221, no. 1-2, pages 21 - 32 | - HERTRAMPF T ET AL., "Tissue-specific modulation of cyclooxygenase-2 (Cox-2) expression in the uterus and the v. cava by estrogens and phytoestrogens", MOL CELL ENDOCRINOL, (2005), vol. 243, no. 1-2, doi:doi:10.1016/j.mce.2005.08.007, pages 51 - 7, XP005158084 DOI: http://dx.doi.org/10.1016/j.mce.2005.08.007 | - HEGELE-HARTUNG C ET AL., "Impact of isotype- selective estrogen receptor agonists on ovarian function", PROC OF THE NATL ACAD SCI USA, (2004), vol. 101, no. 14, pages 5129 - 34 | - HILLISCH A ET AL., "Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design", MOL ENDOCRINOL, (2004), vol. 18, no. 7, doi:doi:10.1210/me.2004-0050, pages 1599 - 609, XP009049742 DOI: http://dx.doi.org/10.1210/me.2004-0050 |